Selling, General, and Administrative Costs: United Therapeutics Corporation vs Jazz Pharmaceuticals plc

Biopharma Giants' SG&A Expenses: A Decade of Divergence

__timestampJazz Pharmaceuticals plcUnited Therapeutics Corporation
Wednesday, January 1, 2014406114000381287000
Thursday, January 1, 2015449119000452612000
Friday, January 1, 2016502892000316800000
Sunday, January 1, 2017544156000330100000
Monday, January 1, 2018683530000265800000
Tuesday, January 1, 2019736942000336200000
Wednesday, January 1, 2020854233000423900000
Friday, January 1, 20211451683000467000000
Saturday, January 1, 20221416967000487000000
Sunday, January 1, 20231343105000477100000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biopharma Giants: SG&A Expenses Over Time

In the competitive world of biopharmaceuticals, managing operational costs is crucial. This chart compares the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and Jazz Pharmaceuticals plc from 2014 to 2023. Jazz Pharmaceuticals has consistently outpaced United Therapeutics in SG&A spending, with a notable peak in 2021, where their expenses were nearly three times higher than United Therapeutics. This trend highlights Jazz's aggressive market strategies and expansion efforts. Meanwhile, United Therapeutics has maintained a more conservative approach, with expenses peaking in 2022. Over the decade, Jazz's SG&A expenses grew by approximately 230%, while United Therapeutics saw a more modest increase of around 25%. This divergence in spending strategies reflects differing priorities and market approaches, offering insights into each company's operational focus and growth ambitions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025